H.R. 6227 · 118th Congress
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
Introduced on Nov 3, 2023 by David Schweikert (R-AZ-1). 35 cosponsors, 14 of them from another party. Latest action (Nov 10, 2023): Referred to the Subcommittee on Health.
- Stage
- Introduced
- Introduced
- Nov 3, 2023
- Cosponsors
- 35
- 14 from the other party
- Policy area
- Health
Progress
The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.
- Introduced
- 2Reported by committee
- 3Passed one chamber
- 4Passed both chambers
- 5Sent to the President
- 6Became law
Official title
To amend the Federal Food, Drug, and Cosmetic Act to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.
Subjects
- Cardiovascular and respiratory health
- Drug safety, medical device, and laboratory regulation
- Health promotion and preventive care
- Prescription drugs
Summary
By the Congressional Research Service (Introduced in House, Nov 3, 2023). Public domain.
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.
Sponsor and cosponsors
Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.
Democrats · 14
- Yadira CaraveoD-CO-8original
- Jim CostaD-CA-21original
- Ruben GallegoD-AZ-3original
- Raúl M. GrijalvaD-AZ-7original
- Mike LevinD-CA-49original
- Brittany PettersenD-CO-7signed on Nov 29, 2023
- Melanie A. StansburyD-NM-1signed on Nov 29, 2023
- Eric SwalwellD-CA-14signed on Nov 29, 2023
- Scott H. PetersD-CA-50signed on Dec 5, 2023
- Kevin MullinD-CA-15signed on Dec 13, 2023
- Lizzie FletcherD-TX-7signed on Dec 19, 2023
- Susie LeeD-NV-3signed on Dec 19, 2023
- Teresa Leger FernandezD-NM-3signed on Jan 11, 2024
- Andrea SalinasD-OR-6signed on Feb 23, 2024
Republicans · 21
- Kelly ArmstrongR-NDoriginal
- Michael C. BurgessR-TX-26original
- Juan CiscomaniR-AZ-6original
- Monica De La CruzR-TX-15original
- Kevin McCarthyR-CA-20original
- Keith SelfR-TX-3original
- Michelle SteelR-CA-45original
- David G. ValadaoR-CA-22original
- Debbie LeskoR-AZ-8signed on Nov 8, 2023
- Doug LaMalfaR-CA-1signed on Nov 29, 2023
- Jay ObernolteR-CA-23signed on Dec 4, 2023
- John JoyceR-PA-13signed on Dec 13, 2023
- Mariannette Miller-MeeksR-IA-1signed on Dec 19, 2023
- Blake D. MooreR-UT-1signed on Dec 19, 2023
- Stephanie I. BiceR-OK-5signed on Jan 11, 2024
- August PflugerR-TX-11signed on Feb 5, 2024
- Troy BaldersonR-OH-12signed on Feb 23, 2024
- Larry BucshonR-IN-8signed on Feb 23, 2024
- Dan CrenshawR-TX-2signed on Mar 13, 2024
- Diana HarshbargerR-TN-1signed on Mar 13, 2024
- Vince FongR-CA-20signed on Jul 22, 2024
Roll calls
Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.
No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.
History
Every action as published, oldest first. Roll calls link to how each member voted.
- Nov 3, 2023Introduced in House
- Nov 3, 2023Introduced in House
- Nov 3, 2023 · HouseReferred to the House Committee on Energy and Commerce.
- Nov 10, 2023 · HouseReferred to the Subcommittee on Health.
Committees
Committees and subcommittees the measure was referred to.
Agencies in its committees' jurisdiction
Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.
Who lobbied on it
Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.
- Anivive Lifesciences Inc.2 reports
Reports filed in 2023, 2024.
Sources and method
Every figure on this page traces to these records.
- Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
- Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
- House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
- Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
- Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
- Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
- Money and votes are shown side by side; neither explains the other.